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Abstract: Purpose
Existing data do not explain the reason why some individuals homozygous for the
hypomorphic FECH allele develop erythropoietic protoporphyria (EPP) while the
majority are completely asymptomatic. This study aims to identify novel possible
genetic variants contributing to this variable phenotype.
Methods
High throughput re-sequencing of the FECH gene, qualitative analysis of RNA and
quantitative DNA methylation examination were performed on a cohort of 72 subjects.
Results
A novel deep intronic variant was found in four homozygous carriers developing a
clinically overt disease. We demonstrate that this genetic variant leads to the insertion
of a pseudoexon containing a stop codon in the mature FECH transcript by the
abolition of an exonic splicing silencer site and the concurrent institution of a new
methylated CpG di-nucleotide. Moreover, we show that the hypomorphic FECH allele
is linked to a single haplotype of about 20kb in size that encompasses three non-
coding variants that were previously associated with expression quantitative trait loci
(eQTLs).
Conclusion
This study confirms that intronic variants could explain the variability in the clinical
manifestations of EPP. Moreover, it supports the hypothesis that the control of the
FECH gene expression can be mediated through a methylation-dependent modulation
of the pre-mRNA splicing pattern.
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in the discussion we refer to the average frequencies estimated on all the 26 human populations included in 
1000G. 
Minor comments: 
1. "Clinical manifestation of EPP is typically associated with a compound heterozygous genetic background 
at FECH locus", the word 'background' here is incorrect, should read "Clinical manifestation of EPP is typically 
associated with compound heterozygous variants at the FECH locus inherited in an autosomal recessive 
manner". 
Since only 4% of patients inherit two pathogenic variants, the sentence has been corrected as suggested 
removing the last part regarding the inheritance. "Clinical manifestation of EPP is typically associated with 
compound heterozygous variants at the FECH locus”. 
 
2. "It is widely accepted that the aberrant alternatively spliced mRNA is degraded by a nonsense mediated 
decay (NMD) mechanism, leading, in the context of the null allele, to sufficient FECH enzyme deficiency". This 
sentence does not make sense, if the mRNA is degraded and the other allele is null - how is there functional 
FECH protein? I think what the authors mean to say is that only a subset of transcripts from the C allele are 
aberrantly spliced? Thus, there is still sufficient FECH protein to prevent EPP? 
Actually, the use of cryptic alternative acceptor splice site is also observed in individuals carrying the T allele. 
Carriers of the C allele show an increased utilization of this site resulting in a higher proportion of aberrantly 
spliced transcripts. This leads to an additional FECH enzyme deficiency, which is necessary for protoporphyrin 
overproduction and clinical symptoms. The sentence has been changed for clarity. 
 
3. I would recommend figure S1 be included in the main manuscript to aid in interpretation of results. For 
instance, within figure1 as the first 'A' panel. Figure S1 needs a legend, what are the # and other symbols. 
Also it would be helpful if the resulting FECH protein annotation was added to this figure e.g. c.464-
1169A>C (p.Ala155GlyfsTer22) 
The figure S1 has been incorporated in the figure 1 as suggested. The legend was already included in the 
text as well as the explanations of the symbols in the figure itself. 
4. (p.(Ala155GlyfsTer22)) should be (p.Ala155GlyfsTer22) 
No, the HGVS general recommendations for sequence variant nomenclature 
(http://varnomen.hgvs.org/recommendations/general/) suggest to use of (parentheses) to indicate 
uncertainties and predicted consequences; NC_000023.9:g.(123456_234567)_(345678_456789)del, 
p.(Ser123Arg). Also in our case the consequences at protein level are predicted, thus we indicated this 
fact as p.(Ala155GlyfsTer22). In the text there are other 2 parentheses because of the sentence construction.  
 
5. "A novel deep intronic variant (c.464-1169A>C) and an annotated low frequency genetic variant 
(c.804+659G>A; rs754770993, frequency in 1000 genomes 0; Kaviar 0,000115)" Frequency in 
bravo/topmed? What was the data source referenced in Kaviar? 
Frequencies in TopMed, gnomAD and ExAC have now been included in the text.  Kaviar is a large database 
that incorporates data of human genetic variation from more than 30 independent studies. A complete list 
of the datasets that are currently incorporated in Kaviar can be found at: 
http://db.systemsbiology.net/kaviar/cgi-pub/Kaviar.pl?show=sources . Details concerning the version of 
Kaviar used in this study are provided in the materials and methods section. 
6. "For PCR amplicon, covering exons 4 to 8" amplicon should be amplification. In general the manuscript 
needs to be thoroughly proofed for grammatical and style errors such as this. 
The manuscript has now been subjected to a further round of proofing, which was performed by a native 
speaker (see acknowledgments). 
7. While the analysis of the sequences around the known c.68-23 A>T and c.315-48 T>C eQTLs indicated 
formation of new ESS sites ((TT)TCATGT(GAG) and (G)GCTG(CTAA) respectively). This section would be 
more relevant to include in the next section focusing on the GTC haplotype. 
The sentence has been moved as required 
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ABSTRACT  
Purpose 
Existing data do not explain the reason why some individuals homozygous for the hypomorphic 
FECH allele develop erythropoietic protoporphyria (EPP) while the majority are completely 
asymptomatic. This study aims to identify novel possible genetic variants contributing to this variable 
phenotype.  
Methods 
High throughput re-sequencing of the FECH gene, qualitative analysis of RNA and quantitative DNA 
methylation examination were performed on a cohort of 72 subjects.  
Results  
A novel deep intronic variant was found in four homozygous carriers developing a clinically overt 
disease. We demonstrate that this genetic variant leads to the insertion of a pseudoexon containing a 
stop codon in the mature FECH transcript by the abolition of an exonic splicing silencer site and the 
concurrent institution of a new methylated CpG di-nucleotide. Moreover, we show that the 
hypomorphic FECH allele is linked to a single haplotype of about 20kb in size that encompasses three 
non-coding variants that were previously associated with expression quantitative trait loci (eQTLs). 
Conclusion  
This study confirms that intronic variants could explain the variability in the clinical manifestations 
of EPP. Moreover, it supports the hypothesis that the control of the FECH gene expression can be 
mediated through a methylation-dependent modulation of the pre-mRNA splicing pattern. 
 
KEYWORDS 
erythropoietic protoporphyria; deep intronic pathogenic variant; eQTLs; CpG sites; pre-mRNA 
splicing pattern 
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INTRODUCTION  
Erythropoietic protoporphyria (EPP, MIM#177000) is a heritable metabolic disorder resulting from 
a reduction, to less than 35% of normal levels, of ferrochelatase (FECH, EC 4.99.1.1) activity.1 FECH 
is the last enzyme of the heme biosynthetic pathway and reduced activity leads to significantly 
elevated metal-free protoporphyrin (PPIX) levels mainly in erythrocytes and subsequently in skin and 
liver, causing clinical manifestations of the disease.2 EPP patients experience severe cutaneous 
phototoxic reactions in sun-exposed areas since their early childhood. Besides this, the accumulation 
of PPIX in the liver may lead to mild hepatic injury and, in approximately 2% of cases, to severe 
cholestatic damage progressing to liver failure and requiring consequent liver transplantation.3 
Clinical manifestation of EPP is typically associated with compound heterozygous variants at FECH 
locus, mapped to chromosome 18q21.3. Currently about 200 pathogenic variants are reported in the 
Human Gene Mutation Database (HGMD professional v2018.3 
http://www.hgmd.cf.ac.uk/ac/index.php). Although a limited number of patients, carrying two null 
FECH alleles has been reported,4 in the majority of the affected individuals, a rare null FECH allele 
is co-inherited in trans with a common hypomorphic allele that is associated with decreased levels of 
FECH gene expression.5, 6 This hypomorphic FECH allele is characterized by the presence of a 
common variant in intron 3 (c.315–48T>C, C variant, rs2272783), which modulates the usage of a 
cryptic alternative acceptor splice site, 63 bp upstream of the constitutive site (Figure 1A). It is widely 
accepted that the aberrant alternatively spliced mRNA is degraded by a nonsense mediated decay 
(NMD) mechanism, leading, in the context of the null allele, to additional deficiency of 
ferrochelatase, which is necessary for protoporphyrin accumulation and clinical symptoms.7, 8 Recent 
independent studies have reported a few cases with a mild EPP phenotype in the presence of the C 
variant in homozygosis9, 10 while others have described a late-onset of the EPP phenotype, secondary 
to a myelodysplastic syndrome.11 The C variant is normally present in healthy human populations, 
with frequencies ranging from 1% - 5% in Africa and Europe to 32% - 37% in East Asia and in 
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America. Increased frequencies of the C variant are not associated with an increase in the prevalence 
of EPP, even in populations where a high percentage of homozygous subjects (19–22%) is observed.12 
Several independent studies have reported that two other common variants, c.1–252A>G in the 
promoter (G variant, rs17063905) and c.68–23C>T in intron 1 (T variant, rs2269219) are consistently 
found in association with the c.315-48T>C variant in EPP patients, forming a so-called GTC 
haplotype.13, 14 Interestingly all three variants of the GTC haplotype are associated with expression 
quantitative trait loci (eQTL) that reduce the expression of the FECH gene according to the GTEX 
study (GTEx Analysis Release V7 (dbGaP Accession phs000424.v7.p2)), suggesting a possible role 
for the GTC haplotype as a whole in the pathogenesis of EPP. However, at present it is still unclear 
whether a homozygous GTC state in isolation is sufficient to provoke EPP.15 In this study, we have 
performed a high throughput targeted re-sequencing of the FECH locus in a cohort of 72 individuals 
belonging to 24 Italian unrelated EPP families. Notably, five subjects out of 72 were homozygous for 
the hypomorphic GTC allele and showed a variable phenotype where one was completely 
asymptomatic, while others developed a clinically overt disease from childhood. By comparing 
hypomorphic GTC alleles between patients and unaffected carriers, the study aimed to identify 
possible functional variants responsible for the variable outcome of EPP. 
METHODS 
Study subjects  
All patients were diagnosed based on the clinical history of photosensitivity in the presence of plasma 
porphyrin peak at 635nm and high levels of protoporphyrin in the erythrocytes and feces. The 
sequence of the FECH gene was also determined by Sanger sequencing. Both parents when available 
and healthy relatives were recruited in order to facilitate the reconstruction of the hypomorphic GTC 
haplotype. The study was approved by the Fondazione IRCCS Ca’ Granda ethics committee (n°2952, 
12-18-2015) and all the subjects signed informed consent prior to their inclusion in the study (Table 
S1).  
Targeted FECH re-sequencing  
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A custom enrichment panel was designed by the means of the Agilent SureDesigntm software to 
capture 90.2 Kb of genomic DNA, from 40Kb upstream to 10kb downstream of the FECH gene, 
including all exons and introns (chr18 55202704-55292856 on the hg19 human genome assembly). 
Genomic DNA was extracted from peripheral blood using the Maxwell®16 Automated System 
(Promega Corporation, Madison, USA) and spectrofluorometrically quantified using QuantiFluor® 
One dsDNA kit on GloMax Discover® instrument (Promega Corporation, Madison, USA) according 
to manufacturer's instructions. Standard Haloplex Target Enrichment system procedure (Agilent 
Technologies, Santa Clara, USA) was applied for library preparation and 150 bp paired–end reads 
were generated using a MiSeq sequencer (Illumina, San Diego, USA). Several coverage metrics were 
recorded in order to define the accuracy and possible limitations of the enrichment panel. 
Variant calling, phasing and association tests 
Variant calling was performed by the CoVaCS pipeline as described by Chiara et al. 2018.16 The 
Annovar software was employed for variants annotation.17 The following annotation resources were 
considered for the estimation of allele frequencies: ExAC (version 1.0 updated 02-27-2017)18, 1000G 
(phase3)19, gnomAD (version 2.1, updated 12-10-2018)18, dbSNP (build 151)20, Kaviar (version 
160204-Public)21 and TopMed (freeze5, accessed on 02-28-2019, nhlbiwgs.org). Refseq (release 
106)22 was considered for genes and transcript annotations, Clinvar (version 1.55, updated 12-26-
2018)23 and HGMD-Pro 2018.324 for the annotation of disease–causing variants and the dbNSPF 
(v4.0b1, updated 12-30-2018)25 database for the evaluation of non-synonymous substitutions effect. 
Nucleotides are numbered based on the FECH NM_000140.3 - Human Refseq transcript, with the A 
of the ATG initiation codon as ‘+1’. 
Adapted functions of the R alleHap package (https://cran.r-
project.org/web/packages/alleHap/index.html) were used to obtain the most likely genotype 
combination and haplotype phasing for trios. Single marker association statistics and visualization of 
local linkage disequilibrium (LD) were obtained using the Haploview software 
(https://www.broadinstitute.org/haploview/haploview).26  
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FECH gene expression analysis using public data 
Vcf files containing the genetic profiles of the individuals included in the GTEx27 and 1000G studies 
were retrieved from the dbGaP database28 (dbGaP Study Accession: phs000424.v7.p2 ) and the 
1000G data repository (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/) respectively. 
The expression profiles of the FECH gene were obtained directly from the GTEx portal 
(https://storage.googleapis.com/gtex_analysis_v7/rna_seq_data/GTEx_Analysis_2016–01–
15_v7_RNASeQCv1.1.8_gene_tpm.gct.gz). A custom Perl script was used to extract haplotypes for 
the FECH gene and cross-reference genetic with expression data. A total of 136 individuals, for which 
both genotypic and gene expression data were available, were considered.  
Qualitative RNA analysis by RT-PCR 
Total RNA was isolated from peripheral blood of patients, using the LEV simplyRNA Blood Kit for 
Maxwell®16 (Promega Corporation, Madison, USA), according to the protocol described in 
Fiorentino et al. 2016.29 400 ng of total RNA were reverse transcribed using the Superscript IV VILO 
Master Mix (Thermo Fisher, San Francisco, USA) following the protocol supplied with the kit. 50 ng 
of cDNA was amplified using 10 pmol/μL of each primer, in the presence of 1X buffer, 1.5mM Mg2+, 
0.2 mM dNTPs, and 1.25 U of Taq polymerase. The reaction was performed under the following 
conditions: an initial step at 94 °C for 5 min followed by 35 cycles of denaturation at 94 °C for 30 s; 
amplification at 60 °C for 30 s and 72 °C for 1 min; and a final extension at 72 °C for 10 min. The 
region spanning from exons 1 to 8 of the FECH gene was amplified using different sets of primer 
pairs and directly sequenced (Table S2). In order to increase the signal of abnormal bands during 
sequencing, cDNA product were re-amplified with original and nested primers. Splicing motifs 
analysis was carried out through Human Splicing Finder v.3 software 
(http://www.umd.be/HSF3/index.html).30 
DNA methylation analysis 
For DNA methylation analysis 500 ng of DNA was treated with bisulfite using the EZ–96 DNA 
methylation-Gold kit (Zymo Research, CA, USA) in a final elution volume of 200 μL according to 
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manufacturer's instructions. Bisulfite-treated DNA was amplified with PCR for each region of 
interest: a PCR reaction in 50 μL volume was carried out with 25 μL of Hot Start GoTaq Green Master 
mix (Promega), 1 pmol of forward primer, 1 pmol of reverse primer and 25 ng of bisulfite-treated 
genomic DNA. Biotin-labeled primers (forward or reverse, depending on the assay) were used to 
purify the PCR products with Sepharose beads. PCR products were bound to a Streptavidin Sepharose 
HP (Amersham Biosciences, Uppsala, Sweden), purified, washed, denatured with 0.2 M NaOH and 
washed again with the Pyrosequencing Vacuum Prep Tool (Pyrosequencing, Inc., Westborough, MA, 
USA). Then, pyrosequencing primer (0.3 µm) was annealed to the purified single-stranded PCR 
product, and methylation analysis was performed by PyroMark MD Q96 (Pyrosequencing, Inc. 
Westborough, MA, USA). PCR cycling conditions and primer sequences are shown in Table S3. 
RESULTS 
Targeted resequencing of the FECH gene  
Observed coverage levels, which are reported in Table S4, were well in line with the 
recommendations for the usage of NGS based resequencing assays in diagnostics: 92.5% of the target 
regions were covered at 10x or more and 87.8% at 20x or more. However, a consistent proportion of 
the targeted regions, corresponding to 14.5% of total target was covered by 10x or less reads in more 
than 20 samples, suggesting systematic biases in the coverage profiles. Accordingly, these regions 
were excluded from subsequent analyses. Interestingly we notice that 94.27% of the low coverage 
regions correspond with RepeatMasker31 annotated repeats in the hg19 human genome assembly, 
reflecting either a reduced rate of mapping of short Illumina reads in highly repetitive regions of the 
genome or the possible presence of large structural rearrangements or repeat copy number alterations. 
A markedly increased coverage (no single region below 20x in all the samples) was observed for the 
exonic and non-repetitive regions (Table S4). 
Genotyping and haplotype phasing  
A total of 510 variable sequence positions at the target FECH region were identified in the 72 
individuals included in this study (Table S5). Of these 109 were completely novel and had never been 
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reported in any of the publicly available repositories of human genetic variations considered in this 
study (i.e., 1000G, gnomAD, ExAC, TopMed and Kaviar). Importantly, all the EPP–causing variants, 
previously identified by the Sanger sequencing, were recovered also by the NGS based assay. In fact, 
re-sequencing confirmed that among the 24 patients, 18 co-inherited a null allele in trans to the 
hypomorphyic allele, 2 carried only one hypomorphic allele and no pathogenic variants in trans, 
while 4 carried two hypomorphic alleles. Notably the asymptomatic mother of a patient with classical 
genotype also carried two hypomorphic alleles. The most likely genotypes were obtained by 
haplotype phasing for all the 72 sequenced subjects in order to compare single alleles.  
Two novel deep intronic variants are associated with EPP  
A novel deep intronic variant (NG_008175.1(FECH_v002):c.464–1169A>C) and an annotated low 
frequency genetic variant (c.804+659G>A; rs754770993, frequency in 1000G and ExAC 0; Kaviar 
and gnomAD 0,0001; TopMed 0.0002), were found in four patients carrying the hypomorphic allele 
in homozygosis and displaying a clinically overt disease. These variants, which were located, 
respectively, in introns 4 and 7 of the FECH gene, were inherited in cis with one of the two 
hypomorphic alleles from one of the two parents. More importantly, they were not observed in the 
homozygous hypomorphic subject without symptoms of EPP and in all the other 20 patients carrying 
the hypomorphic allele.  
c.464–1169A>C variant activates a pseudo–exon in intron 4 
RT-PCR was performed in order to investigate possible effects of the c.464–1169A>C deep intronic 
variant on the FECH splicing pattern. For amplification, covering exons 4 to 8 an additional longer 
band was amplified only in four symptomatic GTC homozygous patients (Figure 1B). Re-
amplification of the exon 4-8 cDNA fragments with the original and nested primers revealed that the 
longer band is caused by an insertion between exons 4 and 6 and not between exons 7 and 8 (Figure 
1C). Direct sequencing showed an insertion in the transcript of a pseudo–exon of 156bp containing a 
stop codon sequence (Figure 2). This exon, located in intron 4, also encompassed the c.464–1169A>C 
deep intronic variant and presented common consensus sequences of splicing. 
STOP 
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The c.464–1169A>C variant is associated with the disruption of an exonic splicing silencer (ESS)  
Functional annotation of the deep intronic variants by the means of the human splicing finder program 
(HSF) was performed in order to identify possible functional effects on the splicing pattern. Three 
different algorithms predicted the disruption of an exonic splicing silencer site (ESS) in intron 4, by 
the c.464–1169A>C substitution. The ESS wild type sequence ((GT)TAGGAG) was also recognized 
as a core binding site for the hnRNP A1 protein; in the presence of the ESS mutated sequence 
((GT)TCGGAG) this binding site was disrupted. No relevant alterations were reported for the 
c.804+659G>A variant.  
A single GTC haplotype is linked to the hypomorphic allele 
Using simple Mendelian inheritance rules, 446 variants were assigned to distinct haplotypes of FECH 
gene. Of these, 176 were found to be consistently shared among all the individuals carrying the 
hypomorphic FECH allele. Segregation analysis was carried out to establish the parental origin of 
each variant and the most likely genotype combination in phasing with the c.315–48 C was obtained 
for each trio. The comparisons of the selected hypomorphic alleles showed that 23 out of 24 unrelated 
patients shared an identical haplotype of FECH gene of about 20 kb in size. The same presumed 
haplotype was also identified in both copies of the FECH locus in the five individuals homozygous 
for hypomorphic allele. The haplotype spans from 3.7 kb upstream to the transcription start site 
(rs75861770) to 1.7 kb in the intron 4 (rs11874117) and contains 47 annotated SNPs including the 
c.1–252 G and the c.68–23 T variants (Figure 3). Interestingly only a single recombination event of 
the proposed haplotype is observed, that is one patient, where only the portion from intron 1 
(rs32166686) to intron 4 is retained.  
The GTT and ATC haplotypes are associated with reduced FECH mRNA levels 
Among the 47 SNPs included in the observed haplotype only the known c.315–48 C variant was 
never observed in trans to a mutated FECH allele in asymptomatic carriers. Notably only two parents 
presenting very light accumulation of protoporphyrins (6.3 and 5.2 vs n.v <3 mcg/gHb.), with no 
clinical manifestations of EPP, inherited in trans to the mutated allele the c.1–252 A>G and c.68–
Exon 4 
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23C>T variants; these other two known substitutions are part of GTC haplotype. A chi-squared test, 
as implemented by the Haploview software, was used to evaluate the level of association for single 
markers. The analysis confirmed that the c.315–48 C variant has the strongest association with the 
disease (p-value: 3.29 E–7) while a reduced but still significant association is observed for the c.68–
23T (p-value: 7.03E–6) and c.1–252 G (p-value: 2.45E–5) variants (Table S6). An extensive analysis 
of the publicly available genotypic and gene expression data (GTEX) of 136 individuals included in 
the GTEX study evidenced a significant decrease in the expression level of the FECH gene both in 
the carriers of GTT and GTC haplotypes. Consistent with previous observations this decrease is more 
pronounced in the individuals carrying the GTC haplotype (Figure 4A). 
Notably, while the GTC haplotype is over-represented in our cohort of patients with respect to a 
population of healthy individuals, we observe no, or very weak, evidence of recombination within 
the GTC haplotype in the healthy population (Figure 4B). Interestingly, among the patients included 
in the present study, only one individual with a clinically overt disease carried a “modified” ATC 
haplotype. At the same time, no EPP patient carried the ACC haplotype, which is as frequent as the 
ATC (Figure 4B). Of note, a LOD score of 12.65 was found between the T and C variants where 
LOD > 2 indicates significant linkage disequilibrium (LD) (Figure S1). Moreover, the HSF analysis 
of the sequences around the c.68–23 A>T and c.315–48 T>C eQTLs indicated formation of new ESS 
sites ((TT)TCATGT(GAG) and (G)GCTG(CTAA) respectively).  
Differential methylation around FECH variants are associated with altered splicing patterns 
Considering the emerging role of intragenic methylation in the regulation of the alternative splicing, 
different CpG sites along the gene were analyzed by bisulfite pyrosequencing. As expected for an 
expressed gene, the methylation in the promoter region was minimal and no measurable difference 
was noted between patients. Surprisingly, the patients carrying the c.464–1169A>C deep intronic 
pathogenic variant presented a new methylated CpG site which was not observed in other patients 
with a classical GTC haplotype or in unaffected subjects. Conversely, the c.68–23T variant in intron 
1 and the variant in intron 7 abolished commonly methylated CpG sites. No alteration was detected 
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in the region encompassing the c.315-48 C variant of intron3 (Table 1). In order to establish whether 
the c.68-23T variant also affects the modulation of the FECH splicing, a forward primer 
encompassing the exons 1 and 3 and a reverse primer located in the region of alternative splicing of 
intron 3 were used for RT-PCR (Table S2). The direct sequencing of the PCR product confirmed the 
presence of an isoform of splicing showing a complete skipping of the constitutive exon 2 and the 
insertion of the 63bps of intron 3 (Figure S2). The identified sequence is reported in Ensembl as a 
non-coding processed transcript (ENST00000585699.1). 
DISCUSSION 
In this study, by using deep targeted resequencing of the FECH gene we report the first evidence of 
a deep intronic variant causing erythropoietic protoporphyria (EPP). We demonstrate that the c.464–
1169A>C intronic substitution (p.(Ala155GlyfsTer22)) disrupts, likely through the institution of new 
methylated CpG site, an exonic splicing silencer (ESS) site causing the insertion of a “cryptic exon” 
containing a stop codon, in the mature FECH transcript. It is now clear that constitutive and 
alternative splicing events in higher eukaryotes are finely regulated through the concerted recognition 
of multiple well-defined and weak cis-acting elements by trans-acting factors. Depending on the 
effect they exert, these weak cis-acting elements are generally referred to as either enhancers or 
silencers.32 Several lines of evidence suggest that silencers have a fundamental role in preventing 
pseudoexon inclusion in mature transcripts and in defining constitutive exons by suppressing nearby 
decoy splice sites.33 Additionally, DNA methylation is emerging as an important factor in exon 
selection by the splicing machinery and also in the regulation of alternative splicing.34 In particular, 
the increase of DNA methylation has been reported to promote the inclusion of alternative exons.35 
All these considerations are highly consistent with the proposed significance of the c.464–1169A>C 
variant. 
Our data also provide independent confirmation that clinically overt EPP is strongly associated with 
inheritance of the c.315–48 C variant and that, clinical expression of disease typically occur when 
this hypomorphic allele exists in trans to a null FECH allele. These results also confirm that the 
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c.315–48 C variant in isolation is necessary but not sufficient to cause an overt disease even when 
inherited in homozygosis. It was recently shown that abnormal splicing events are twice as frequent 
in the presence of the c.314–48 C variant in heterozygosis. At the same time, this figure does not 
increase further in homozygous C EPP patients, which show FECH mRNA levels comparable to 
those of EPP patients with a classical genotype.15 Moreover, FECH activity in Japanese healthy 
controls, homozygous for the C variant, was reported to be <50% of that reported for non-carriers, 
but anyway increased by 40% with respect to that of EPP patients.36 Therefore the presence of the 
deep intronic pathogenic variant identified in this study, in cis with the c.315–48 C variant in one of 
the two hypomorphic alleles, could explain, at least in part, the variable outcome of EPP in 
homozygous C individuals worldwide. 
According to our findings in the majority of our unrelated patients (23 of 24), the c.315–48 C variant 
is linked to a single haplotype encompassing the first 20Kb of the FECH gene. Among all the variants 
included in this haplotype, however the Haploview association analysis, recovered a significant 
association with EPP only for two other known variants: c.1 –252 G and c.68–23T. Both these single 
variants were functionally evaluated by in vitro analyses. The c.1–252A>G substitution in the 
promoter region has been reported to result in a slight decrease in FECH transcriptional activity.37 
While, the c.68–23C>T substitution in intron 1, was found to alter the pre-mRNA structure leading 
to exon 2 skipping during the splicing process.38 Notably in our cohort, both these single variants 
were inherited in trans to a null allele in two subjects presenting very mild accumulation of 
protoporphyrins without any apparent clinical symptoms. This evidence suggests that both variants 
in trans to a null FECH allele can result in a slight decrease in the FECH activity and in a mild PPIX 
accumulation but are not sufficient to consistently cause clinical expression of the disease. Consistent 
with this hypothesis, extensive publicly available gene expression data from the GTEX study provide 
evidence for a decrease in the expression level of the FECH transcript also in individuals carrying the 
GTT haplotype. Taken together these observations are consistent with the idea that the hypomorphic 
allele is prevalently inherited in the form of the GTC haplotype. Considerations on the relative 
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frequency of the GTT and GTC haplotypes (GTT approx. 22% and GTC approx. 11%) in the healthy 
population suggest that GTC is a derived form of the GTT haplotype and that it is associated with a 
more marked decrease in the expression levels of the FECH gene. 
The observation that in our cohort, one symptomatic patient was not carrying the c.1–252 G variant 
in the promoter suggests that this might not be required to induce an overt disease. On the contrary, 
all patients showed extended levels of linkage disequilibrium between the c.68–23T and c.315–48 C 
variants, located in introns 1 and 3 respectively, supporting the hypothesis that both are necessary for 
the lower steady state level of FECH mRNA resulting in protoporphyrin overproduction and 
photosensitivity. Importantly both these variants are associated with the creation of new exonic 
splicing silencer sites (ESS) according to the HSF tool. Moreover, we demonstrate that the c.68–23T 
variant alters the DNA methylation pattern by abolishing a methylated CpG site, with an opposite 
effect with respect to the c.464–1169A>C deep intronic pathogenic variant. Additionally, the 
identification of a non-coding splicing isoform, with a complete skipping of the constitutive exon 2 
and the insertion of the 63bps of intron 3 strongly supports the conclusion that both the variants are 
required for clinically relevant down-regulation of the FECH gene. Considerations regarding the 
relatively low frequency of the ATC and ACC with regards to the GTC haplotype, suggest that the 
functional characterization of the T variants warrants further investigation and probably requires the 
study of a larger cohort of EPP patients worldwide.  
In conclusion, our findings suggest that although the majority of EPP causing variants has been shown 
to have a “radical” effect on the coding sequence of the FECH gene, the presence of non-coding 
variants in pathogenic process should consistently be evaluated especially in EPP patients carrying 
only one hypomorphic allele. Moreover, we believe that this study supports the recent findings that 
methylation-dependent modulation of the pre-mRNA splicing patterns may function directly to 
control gene expression levels through the incorporation of “poison exons” leading to NMD.39, 40 All 
in all the findings of this study confirm the validity of the hypothesis that “hidden” sources of 
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variability that are not normally considered in clinical genetic screenings might explain at least in 
part the variability in the clinical manifestations of diseases with incomplete penetrance. 
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FIGURE LEGENDS: 
Figure 1: Scheme of the transcriptional isoforms of the FECH gene analyzed in this study and 
RT-PCR experiments. In Panel A, gray stars are used to indicate the variants that form the GTC 
haplotype, the black triangle indicates the deep intronic variant in intron 4, identified in this study and 
the gray point indicates the common variant in intron 7. The asterisk marks the presence of a stop 
codon in the mature transcript. Primers used for the RT-PCR and nested RT-PCR are also displayed. 
Panel B shows the PCR product spanning exons 4 to 8. Lane M is the molecular weight marker. The 
GTC homozygous symptomatic patients carrying the deep intronic pathogenic variant are indicated 
as Pt1 to Pt4. The following individuals were used as controls: an asymptomatic GTC homozygous 
carrier, an EPP patient with the common GTC haplotype trans to a pathogenic variant and an healthy 
subject. Panel C shows the re-amplification of the PCR fragment with primers encompassing exons 
4–8, 7–8, and 4–6, respectively. 
 
Figure 2: Sanger sequencing of the PCR product encompassing exons 4-6. The sequence shows 
the insertion of a fragment corresponding to a portion of intron 4 into the FECH transcript. The upper 
panel shows the beginning of the inserted sequence, the middle panel highlights the presence of a 
stop codon and the bottom panel shows the junction with exon 4. 
 
Figure 3: Sequence Logo of the conserved haplotype associated with the hypomorphic allele. 
Common SNPs that form the haplotype are designated by their respective dbSNP rs code (X-axis). A 
red rectangle is used to illustrate the polymorphic positions that are conserved between all the carriers 
of the haplotype. The G (rs17063095), T (rs2269219), and C (rs2272783) variants are marked by a 
purple square. 
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Figure 4: Comparison of FECH gene expression in publicly available data. A Boxplots of fold 
change of expression levels of FECH in 136 individuals from the GTEx study carrying the GTC, 
GTT and ATC haplotypes. Median expression of FECH across all the 48 tissues considered in GTEx 
is used as the baseline for the calculation of the fold change. Fold changes are expressed using a base 
2 logarithmic scale. Values lower than 0 indicate down-regulation. Values higher than 0 indicate up 
regulation. B Barplot of haplotype frequencies in a healthy population and in our cohort EPP patients. 
Haplotypes are indicated based on the G (rs17063095), T (rs2269219), and C (rs2272783) variants. 
 
Table 1: DNA methylation analysis.  
Methylation levels are reported in the form of dinucleotides percentage of methylation. Relevant 
differences between the genotype are underlined. A gray scale is used to indicate low, medium and 
high levels of methylation. 
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Table 1: The results of DNA methylation analysis.  
The numbers indicate the percentage of methylation of each analyzed dinucleotides. The relevant differences according to the genotype are underlined. The gray scale indicates 
low, medium and high levels of percentage of methylation. 
 
 
 
 
Analized patient CTRL1 CTRL2 CTRL3 1561 1553 1574 1611 1655 1704 717 1535 1185 713 1525 1526 1169 1262 1382 1683 1448
Genotype ACT/ACT ACT/ATT ATT/ATT ACT/ACT ACT/ACT ACT/ACT ACT/ACT ACT/ACT ACT/GTT ACT/GTT ACT/GTT ACT/GTC ACT/GTC ACT/ATC ACT/ATC GTC/GTC GTC/GTC GTC/GTC GTC/GTC GTC/GTC
c.464–1169A>C c.464–1169A>C c.464–1169A>C c.464–1169A>C
Analyzed region CpG dinucleotides c.804+659G>A c.804+659G>A c.804+659G>A c.804+659G>A
Promoter CG1 0,6 1,8 2,0 2,3 0,5 0,0 0,5 0,0 nd 0,0 0,7 8,8 1,0 0,5 3,1 0,9 3,0 0,5 1,2 0,6
Sequencing A CG2 0,0 0,6 1,1 1,1 0,0 0,0 1,7 1,4 nd 0,0 0,0 1,2 0,4 0,0 8,3 1,9 1,1 1,2 0,0 1,0
CG3 4,0 2,6 3,8 4,0 3,7 5,3 3,6 4,6 nd 4,6 5,1 6,5 2,8 1,9 4,5 3,2 3,1 3,3 6,0 2,2
CG4 0,0 0,0 1,1 0,7 0,0 3,4 0,7 0,0 nd 0,0 0,0 1,7 0,0 0,0 0,0 0,0 0,7 0,7 0,0 0,8
CG5 0,7 0,6 0,0 1,1 2,8 0,0 1,2 1,7 nd 0,0 0,0 0,5 1,1 0,0 0,0 0,0 0,6 0,5 0,0 0,0
CG6 0,0 0,0 0,8 0,6 0,0 0,0 0,0 0,0 nd 0,0 0,0 0,5 0,0 1,1 4,0 0,0 0,0 0,6 2,8 0,0
CG7 0,0 0,8 1,9 0,9 0,0 0,0 2,4 1,0 nd 0,0 6,3 1,9 2,1 2,7 3,8 0,0 1,3 1,8 0,0 1,7
CG8 2,9 2,7 2,5 4,0 5,0 4,3 3,5 4,4 nd 11,7 5,0 3,3 4,0 5,2 5,2 3,5 3,2 3,3 6,7 3,3
CG9 1,6 1,9 1,5 1,9 2,3 2,8 4,8 2,6 nd 4,6 3,5 2,7 2,0 2,2 2,3 2,2 1,7 1,5 2,8 1,7
CG10 3,2 3,1 3,0 3,4 5,1 6,2 4,7 6,7 nd 10,0 6,4 3,7 3,0 4,3 6,8 4,2 3,4 3,2 7,1 3,0
CG11 1,6 1,8 1,5 2,0 2,1 2,2 2,3 2,9 nd 1,9 3,5 2,2 1,6 2,5 3,2 1,5 1,6 1,8 4,0 1,9
Promoter CG1 0,0 0,0 1,3 0,0 1,4 1,3 0,0 0,0 0,0 0,0 0,0 0,7 1,6 0,0 0,0 0,0 1,3 0,0 0,0 0,0
Sequencing B CG2 0,9 2,2 1,0 0,0 1,7 0,9 1,0 0,0 0,0 1,5 0,0 1,9 2,0 1,5 0,0 0,0 1,9 2,0 1,8 2,4
CG3 9,8 9,9 9,5 10,9 9,0 8,5 9,8 9,5 16,0 13,7 10,6 6,7 14,2 13,8 14,8 8,3 9,9 8,6 16,8 11,6
CG4 1,0 2,2 1,0 0,0 1,2 1,9 0,0 0,0 0,0 0,0 0,0 1,3 1,6 0,0 2,0 0,0 0,0 0,0 1,6 0,0
CG5 1,7 2,9 2,4 3,9 2,5 2,5 3,5 3,6 0,0 0,0 1,9 2,5 4,4 0,0 2,6 2,3 3,3 3,0 1,7 3,8
CG6 0,0 0,0 0,0 0,0 2,2 0,0 1,1 0,0 0,0 0,0 0,0 1,5 0,0 0,0 0,0 0,0 0,9 0,0 0,0 1,0
CG7 0,0 1,1 0,0 1,2 0,0 2,6 1,2 0,0 0,0 1,5 0,0 0,8 0,0 0,0 0,0 0,0 1,1 2,3 0,0 0,0
Intron 1 CG1 92,7 93,3 93,6 95,1 95,0 92,2 96,3 94,5 96,4 93,3 94,2 97,1 96,7 93,8 93,6 94,3 97,6 95,3 95,9 94,7
CG2 94,5 96,6 96,4 96,0 96,2 96,7 97,1 95,7 96,6 96,4 96,2 97,1 98,4 96,6 96,6 97,0 96,6 95,6 96,8 96,8
CG3 pol c.68-23C>T 72,0 38,4 3,6 73,8 66,9 71,3 75,6 74,9 38,2 39,4 32,0 41,6 42,7 38,9 34,6 2,2 2,2 3,8 2,5 3,2
CG4 82,8 74,3 75,4 80,7 72,8 82,6 82,9 80,1 84,5 82,2 73,9 84,5 80,6 77,8 75,6 69,0 84,3 71,1 83,5 79,9
CG5 73,4 66,5 67,8 72,9 64,9 70,0 74,5 72,2 78,6 73,4 66,3 76,2 65,1 72,1 70,0 60,7 78,7 63,4 78,1 72,7
CG6 83,2 76,1 78,2 79,5 68,1 76,9 78,2 79,7 82,6 77,6 68,7 83,6 77,7 79,6 76,5 73,3 84,4 65,9 81,9 77,1
Intron3 CG1 95,6 92,2 93,3 88,6 91,4 91,1 91,3 89,9 92,1 92,5 90,5 91,0 85,3 92,9 92,7 90,5 93,5 92,3 92,0 88,7
CG2 85,1 81,0 81,0 86,0 83,3 80,3 80,9 79,6 82,6 84,5 82,8 84,3 83,5 84,7 82,3 83,9 80,7 81,4 80,5 85,1
CG3 80,1 89,6 93,3 82,0 89,2 93,8 88,8 87,5 93,0 85,9 89,5 82,1 67,2 88,8 87,2 82,2 87,7 92,2 94,3 81,2
CG4 99,1 95,4 95,0 95,0 98,0 92,1 95,4 93,0 95,7 94,6 97,9 98,6 96,3 94,1 95,1 93,3 97,9 96,6 96,6 96,8
CG5 98,0 96,6 94,6 96,9 95,0 94,2 93,0 94,9 94,6 95,4 94,3 95,5 94,3 94,5 95,1 95,8 95,7 96,0 94,7 95,7
Intron4 CG1 95,4 99,6 99,7 nd nd nd nd nd nd nd nd 98,7 99,3 96,2 98,3 98,6 99,9 100,0 98,7 98,9
CG2 mut c.464–1169A>C 8,1 6,2 5,6 nd nd nd nd nd nd nd nd 6,9 7,5 11,9 8,7 54,3 53,3 52,2 52,6 7,3
Intron7 CG1 pol c.804+659G>A 97,3 96,6 97,0 nd nd nd nd nd nd nd nd 95,4 96,8 96,2 97,2 55,7 56,0 57,5 57,1 95,2
Table 1
Table S1: list of 72 sequenced subjects; the ID number in bold  indicates proband positive at biochemical tests; in gray 
are underlined individuals homozygous for the GTC hypomorphyic allele among them the c.= in bold indicates the 
presence of new deep intronic variant.  
 
 
Family 
Number  ID number 
sanger sequencing results 
pathogenetic variant Cis  Trans 
1 235 c.215dupT ACT ACT 
  236 c.= ACT GTC 
  237 c.215dupT ACT GTC 
2 689 c.= GTT GTC 
  690 c.215dupT ACT ACT 
  691 c.215dupT ACT GTC 
3 712 c.= GTT GTC 
  713 c.843delC ACT GTC 
  717 c.843delC ACT GTT 
4-5 760 c.400delA ACT GTC 
5 761 c.843delC ACT ACT 
  762 c.843delC ACT GTC 
6 912 c.782C>T ACT GTC 
  922 c.782C>T ACT ACT 
  923 c.= GTT GTC 
7 955 c.67+5G>A ACT GTC 
  956 c.= ACT GTC 
  957 c.67+5G>A ACT ACT 
8 1025 c.215dupT ACT GTC 
  1611 c.215dupT ACT ACT 
  1613 c.= ACT GTC 
9 1154 c.215dupT ACT GTC 
  1655 c.215dupT ACT ACT 
  1656 c.= ACT GTC 
10 1185 c.215dupT ACT GTC 
  1704 c.215dupT ACT GTT 
  1705 c.= ACT GTC 
11 1284 c.215dupT ACT GTC 
  1573 c.= ACT GTC 
  1574 c.215dupT ACT ACT 
12 1352 c.215dupT ACT GTC 
  758 c.= ACT GTC 
  759 c.215dupT ACT ACT 
13 1391 c.343C>T GTT GTC 
  1447 c.343C>T GTT ACT 
  1448 c.= GTC GTC 
  1604 c.= ACT GTC 
  1605 c.= ACT GTC 
  1603 c.= ACT ACT 
14 1526 c.67+5G>A ACT ATC 
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  1535 c.67+5G>A ACT GTT 
  1536 c.= ACT ATC 
  1525 c.67+5G>A ACT ATC 
  1537 c.= ACT GTT 
  1749 c.67+5G>A ACT ACT 
  1750 c.= ACT GTT 
15 1532 c.706-3C>G ACT GTC 
  1561 c.706-3C>G ACT ACT 
  1562 c.= ACT GTC 
16 1550 c.544delC ACT GTC 
  1552 c.= ACT GTC 
  1553 c.544delC ACT ACT 
17 1754 c.215dupT ACT GTC 
  1765 c.= ACT GTC 
  1766 c.215dupT ACT ACT 
18 1691 c.315-15T>A ACT GTC 
19 882 c.= GTT GTC 
20 1061 c.= GTT GTC 
21 1169 c.= GTC GTC 
  1545 c.= ACT GTC 
22 1262 c.= GTC GTC 
23 1382 c.= GTC GTC 
  1534 c.= ACT GTC 
24 1683 c.= GTC GTC 
CTRL family 1 249 c.= ACT ATC 
CTRL 250 c.= GTT ATC 
CTRL 251 c.= ACT ACT 
CTRL family 2 1071 c.= GTT GTC 
CTRL 1072 c.= GTT GCT 
CTRL 1073 c.= ACT GTC 
CTRL family 3 847 c.= ACT GTC 
CTRL family 4 1728 c.= ACT GTC 
 
Table S2: Primers used for RNA Analysis 
Analyzed Region Primer name  Sequence 
Exons 4–8 FECH Q4F 5’GAGGCGGATCCCCCATCAAGATATG3’ 
 FECH Q8R 5’ATTGCCACACCAGTCGGTAG3’ 
Exons 4–6 FECH Q4F 5’GAGGCGGATCCCCCATCAAGATATG3’ 
 FECH Q6R 5’GCCACCTGTCAATAGTGCTCCACT3’ 
Exons 7–8 FECH Q7F 5’GATCATATTCTAAAGGAACTGGACCA3’ 
 FECH Q8R 5’ATTGCCACACCAGTCGGTAG3’ 
Exon 1–3-ins FECH Q1–3F 5’TCCGCGAAGCCGAAAACT3’ 
 FECH Q1–3R 5’GTTTTTTCTGAATAGGAAGTGTCATGA3’ 
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Table S3: Assays conditions used for DNA methylation analysis 
Region  Primer name Sequences Analyzed Sequence 
Promoter  Forward  5’BIO-GTTGAGTTATGGTTGAGGATTTTG3’ 5’CA/GCA/GCCCTCCCA/GACA/
GCA/GCCCA/GCTCATTCA/GC
TACCA/GAACCA/GAAACA/GA
ACA/GAAACC3’ 
 Reverse  5’TCCCCAACCCCCTAACCT3’ 
 Sequencing A  5’TCCCCAACCCCCTAACCT3’ 
 Sequencing B 
 
5’AAACCAAACAAAAACAC3’ 5’A/GCCCCTCA/GCA/GAAAAA
CCCA/GCCCCAACTAAACA/GC
CA/GCTCCCTACA/GTA3’ 
Intron 1 Forward 5’AGGAGGTGTGTGTAGTTTTTAAAATG3’ 5’TTTTTTTGTAGGTTTTTATC/
TGGTTATTTTAGGGGAGC/TG
ATTTTTTATTTT3’ 
 Reverse 5’BIO-AACTTCCACCTCCATAACTAACAAAC3’ 
 Sequencing A 5’AGGAGGTGTGTGTAGTTTTTAAAATG3’ 
 Sequencing B 5’AATTATTTTTTAGTTAGATT3’ 5’TTATGC/TGAGTATTTTAATT
TT3’ 
 Forward 5’BIO-AGTTATGGAGGTGGAAGTTAGGTG3’ 5’ACA/GACCA/GCTACAACTA 
CACCTAACTT CC3’ 
 Reverse 5’CACCTTTCCTCCCAAACAACTT3’ 
 Sequencing A 5’ACTAAACTATTTCTATAATA3’ 
 Sequencing B 5’CACCTTTCCTCCCAAACAACTT3’ 5’ATATCTATTAATATCTACAT
CA/GATAAAAAAAAA3’ 
Intron 3 Forward 5’TAGTTGGGTATTTTTTAGAGAGGG3’ 5’TC/TGTTAAAC/TGTC/TGAA
TTTTTAAGATTTAAG3’ 
 
 Reverse 5’BIO-CAATTCATCCAACAACTTCACC3’ 
 Sequencing A 5’TTTAGTAAGTTGGTATTATTTA3’ 
 Sequencing B 5’TTTAAGATTTAAGAGTAGTA3’ 5’TC/TGTAGGATTGGAGGC/T
GGATTTTTTATTAAGA3’  
Intron 4 Forward 5’BIO-TGGTTTTTAGTTTTTTGGGTTAAG3’ 5’AAAACA/GACATTCCTCCG/
A/TAA3’ 
 Reverse 5’ACCACAAAAAACATTTAAATTAA3’ 
 Sequencing 5’TTTATACCTAAATATATACA3’ 
Intron 7 Forward 5’GTGGGATAGTTAAGAGAAGGTTGT3’ 5’TAAGC/TGTTTTTAA3’ 
 Reverse 5’BIO-TCCCAACTTAATCCTCTATATTCA3’ 
 Sequencing 5’GGGGGGTTTTTATTTAGA3’ 
 
Table S3
SUPPLEMENTAL LEGENDS: 
 
Figure S1: Haploview analysis. The figure shows a large block of the linkage disequilibrium (LD) 
between intron 1 and intron 4 of the FECH gene. The LD block was identified by Haploview using 
the method described in  Gabriel et al. 2002. A LOD score of 12.65 was obtained for the c.68–23T 
and c.315–48 C variants, where a LOD > 2 indicates significant LD. 
 
Figure S2: Sanger sequencing analysis. The figure shows the sequence of the long non-coding 
transcript. The black line indicates the point of junction between the exons. 
 
Table S1: List of the 72 subjects included in this study; probands positive to the biochemical tests 
are indicated in bold; individuals homozygous for the GTC hypomorphyic allele are underlined in 
gray. The c.= symbol in bold is used to indicate the presence of new deep intronic variant.  
 
Table S2: Primers used for RNA Analysis 
 
Table S3: Assays conditions used for DNA methylation analysis 
 
Table S4: Detailed coverage statistics of the target region. Base by base coverage of the targeted 
genomic locus (chr18 55202704-55292856). For every targeted position, the median coverage (Med), 
upper quartile (75th percentile, UQ) and 90th percentile (90th_p) of the coverage distribution, 
calculated on the 72 individuals included in this study are reported. A boolean value (1 yes, 0 no) is 
used to indicate regions showing reduced levels of coverage, that is a upper quartile of the coverage 
distribution lower than 10 (L10) or lower than 20 (L20). Due to limitations in the number of rows 
that are allowed by MS-excels, data are reported in two blocks of columns. A complete table with 
full coverage data for all the individuals included in the study can be retrieved from: 
Supplementary legends
https://github.com/matteo14c/supplementary_files_chiara_dipierro_et_al_ajhg. To avoid the 
aforementioned limitations on the number of rows, the full table is provided in csv (comma separated 
values) and ods (open office spreadsheet) format. 
 
Table S5: List of genetic variants identified in this study. List of the 510 genetic variants identified 
in the targeted genomic locus in the 72 individuals included in the study. Variants are reported by 
genomic coordinates on the hg19 human genome reference assembly. For every polymorphic position 
the following information is also provided: Variant Quality Score (as calculated by the GATK 
haplotype caller), median coverage (Median_Cov), total depth of coverage (DP), allele frequency in 
the cohort (AF), presence/absence (Yes/No) in the collection of publicly available database of human 
genetic variation used in this study. 
 
Table S6: Case-control chi square test results from Haploview analysis 
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